There is no such thing as an AI drug, but AI and ML-models are driving the next wave of new treatments. In this episode, Brandon Allgood, Chief Data Officer at FogPharma and serial entrepreneur at the intersection of ML and Biopharma, shares his insights on how AI is disrupting the traditional process of drug discovery and development.

Join us as we discuss:

• Why AI is so powerful for drug discovery
• What data science needs to learn from engineering
• How drug discovery processes need to be rebuilt with AI models at their core